Member of the Working Committee & Deputy Director of the Management Committee of Suzhou Industrial ParkMr. Ni Qian, Member of the Jinji Lake Business District Working Committee & Deputy Director of the Management CommitteeMs. Shao Jing, Vice General Manager of Suzhou Industrial Park Urban Reconstruction Co., Ltd.Ms. Liu Haixia, President of Medtronic's Coronary and Renal Denervation Business WorldwideMr. Jason Weidman, Vice President of Coronary and Renal Denervation Business Operations in Medtronic ChinaMr. Tao Jia, Founder and CEO of DK MedtechMr. Weng Yulin, Vice President of Corporate Affairs and Corporate Communications for Medtronic Greater ChinaMs. Cao Shan, Vice President of Quality Control and Regulatory Affairs, Health Economic Policy and Medical Insurance at Medtronic Greater ChinaMs. Wang Rong, Vice President of Legal and Compliance, Chief Legal Counsel of Medtronic Greater ChinaMs. Zhang Jingattended the signing ceremony, jointly witnessing this historic moment.
Focus on Clinical Needs, Optimize Coronary Intervention Treatment
Standing Firm, Planning the Journey of the Heart
Coronary heart disease is a major health threat in China. According to the 2022 China Health Statistics Yearbook, the number of patients in China has reached over 10 million. In recent years, with the increase in the population suffering from coronary heart disease in China, the volume of PCI surgeries has also been rising simultaneously. Data released at the 27th Chinese College of Interventional Cardiology Conference showed that since 2019, the number of PCI procedures in China has entered the "million era," with the total registered cases for coronary intervention treatments in mainland China reaching over 1.6 million in 2023 (excluding cases from military hospitals). Against the backdrop of an increasingly urgent demand for coronary intervention treatments, how to further improve the success rate of surgeries and the postoperative prognosis of patients has become a key focus.Adequate lesion preparation is an essential foundation for the success of PCI procedures, and selecting appropriate plaque modification tools and methods to achieve optimal lumen gain is crucial for PCI outcomes. A specialized balloon that offers excellent expansion performance, stability, and deliverability is exactly the surgical tool that clinicians urgently need. In recent years, specialized balloons have developed rapidly, becoming a key solution for coronary artery stenosis-related diseases. The product from the collaboration between Medtronic and DK Medtech—the Diamond Coronary Scoring Balloon—belongs to the new generation of specialized balloons. The addition of this product enriches the solutions provided by Medtronic in the field of coronary treatment, potentially benefiting more patients with coronary heart disease.
Ms. Shao Jing's Excellent Speech: Building a Win-Win Future — Key Pathways for Cooperation Between Enterprises and the Government
At the signing ceremony,Ms. Shao JingIt was pointed out that biomedicine is a strategically emerging industry that Suzhou Industrial Park focuses on fostering and is also the most impressive industrial名片 of the park. In the future, the park will aim to build an open and innovative world-class high-tech park. It will focus on key areas and links in the biomedicine industry, adhere to the highest standards, allocate the best resources, concentrate the best policies, create the best ecosystem, closely align with enterprise development needs, deepen innovation cooperation, and ensure that outstanding enterprises at home and abroad, including DK Medtech and Medtronic, can achieve better development within the park. It is anticipated that with the signing and advancement of new projects by DK Medtech and Medtronic, both parties will leverage their extensive practical experience, mature technical platforms, and quality systems to continuously empower the development and technological progress of the biomedicine industry in Suzhou Industrial Park, creating an even brighter future!
Mr. Jason Weidman's Inspiring Speech: Empowering the Future — The Responsibility of International Enterprises in a New EraMr. Jason WeidmanMedtronic, a global medical technology enterprise rooted in innovation, has witnessed and actively participated in the rapid development and innovation of China's healthcare industry. Over the past 30-plus years of deep engagement in China, Medtronic has not only established a complete industrial chain but also continuously created innovative centers with global influence, actively supporting the development of China’s local healthcare industry. This renewed collaboration with DK Medtech does not merely initiate a new model of cooperation between foreign medical enterprises and emerging local medical companies; it once again demonstrates Medtronic's long-term commitment to the Chinese market. In the future, Medtronic will continue to accelerate the advancement of its localized strategy, further promoting the two-way integration of clinical practice and innovation, empowering local innovation, and driving the upgrading and progress of the healthcare industry. We will also, as always, fulfill our corporate mission by improving the accessibility of medical resources and enabling more Chinese patients to benefit from high-quality medical services.
Mr. Weng Yulin's Excellent Speech: Mapping the Heart Journey — New Ecosystem of Medical Devices Made in China
Mr. Weng YulinDK Medtech and Medtronic Coronary’s first localized collaboration in China focused on drug-coated balloon products, making a highly effective attempt in operational management models. Building on the success of the initial partnership, the two parties have joined hands again to initiate the second phase of localized cooperation targeting a new scoring balloon product. Looking ahead, it is hoped that the two companies will continue to leverage their combined strengths, integrate resources, and accelerate the expansion into both domestic and international markets, helping “Created in China” reach the world. This will enable more patients to benefit earlier from high-quality medical devices produced in China, promoting global public health. It is also anticipated that this collaboration will serve as a cornerstone for further deepening the relationship between the two parties, advancing together toward an even brighter future!Mr. Weng YulinFurther shared in media interviews that this strategic cooperation marks the first attempt at an OEM model, where Medtronic will be responsible for commercialization, and DK Medtech will primarily focus on R&D and production.Through this model, we hope to leverage Medtronic's international brand influence to quickly open up markets both in China and abroad.Collaborating with Medtronic and leveraging its mature marketing channels can accelerate product market access and seize competitive advantages;Leveraging its international brand influence, it quickly opens up markets both in China and abroad.In the future, the company will continue to focus on the field of coronary balloon products, addressing unmet clinical needs and committing to developing targeted and innovative solutions.Secondly, actively expand overseas markets, and through cooperation with multinational companies such as Medtronic, enhance market trust and accelerate the pace of entering overseas markets.On this basis, the product line will also be gradually expanded. The principle is to always adhere to developing distinctive and differentiated products to ensure the competitive advantage of the products in the market.
Mr. Tao JiaIn a recent interview, it was stated that in recent years, Medtronic has fully utilized global resources and local advantages to vigorously promote its localization strategy, accelerating local R&D, production, and training to better serve Chinese doctors and patients. Collaborating with excellent local companies like DK Medtech is an important approach in Medtronic's localization strategy in China. Such collaboration significantly shortens the time for new technologies to enter the market and enriches Medtronic’s full range of product offerings in the coronary field. Looking ahead, Medtronic’s coronary and renal denervation businesses will continue to invest in the two major disease areas of coronary heart disease and hypertension, constantly iterating on products and optimizing treatment outcomes to benefit more patients. Based on the strong foundation of cooperation and synergy with DK Medtech, both parties will join hands to explore further potential for collaboration, seeking more innovative partnership models. Committed to bringing more cutting-edge, efficient, and personalized treatment solutions to the vast number of coronary heart disease patients in China, they aim to jointly write a new chapter in healthcare.
Standing Firmly, Planning the Journey of the HeartStanding Firm, Charting the Course Ahead
Focusing on Coronary Optimization, Creating a Healthy Future Together! Under the witness of several leaders from Suzhou Industrial Park and two enterprises, DK Medical Technology Co., Ltd. and Medtronic (Shanghai) Management Co., Ltd. officially launched their strategic cooperation. This collaboration marks another partnership between DK Medtech and Medtronic in the field of coronary intervention optimization. Standing at a new starting point for win-win cooperation, both parties will fully leverage their respective strengths to jointly promote the rapid development of innovative medical technologies within a standardized framework. By doing so, they aim to better cover the Chinese market with superior medical resources, providing patients with enhanced solutions for interventional therapy needs. Additionally, this innovative business model paves new ways for corporate development. It is anticipated that local emerging medical companies and foreign-invested medical enterprises can collaborate in broader areas to build a larger innovation ecosystem, offering higher-quality medical resources to Chinese patients and contributing to the realization of the "Healthy China 2023" goals.
